7ECKHARD VK. Preclinical safety evaluation of moxifloxacin, a no- vel fluoroquinolone [ J ]. J Antimicrob Chemother, 1999,43 ( 5 ) : 91 -100.
8STASS H, DALHOFF A, KUBITZA D. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-me- thoxy quinolone, administered to healthy subjects [ J ]. Antimicrob Agents Chemother, 1998,42 ( 8 ) : 2060 - 2065.
9SIEFERT HA. DOMDEY-BETYE A. HENNINGER K, et al. Phar- macokineties of the 8-rnethoxyquinolone, moxifloxaein : a comparison in humans and other mammalian species [ J]. J Antimicrob Chemoth- er, 1999,43 ( 5 ) : 69 - 76.
10CONTE JE, GOLDEN JA, MCQUITTY M. Single-dose intrapulmo- nary pharmacokinetics of rifapentine in normal subjects [ J]. Antimi- crob Agents Chemother,2000,44 (4) : 985 - 990.
